nivolumab + ipilimumab + hydroxychloroquine + NG-350A

This is a four-drug investigational combination comprising **nivolumab** (a monoclonal antibody PD-1 checkpoint inhibitor), **ipilimumab** (a monoclonal antibody CTLA-4 checkpoint inhibitor), **hydroxychloroquine** (a small molecule antimalarial and autophagy inhibitor), and **NG-350A** (a next-generation blood-stable adenoviral vector engineered to express a potent agonist anti-CD40 monoclonal antibody specifically within tumor tissue). The combination represents a multi-modal approach intended to enhance anti-tumor immune responses through checkpoint blockade, immune activation, and inhibition of autophagy, with the oncolytic viral vector (NG-350A) potentially augmenting T-cell priming within the tumor microenvironment. NG-350A is being developed by Akamis Bio. This combination is currently experimental, with components (nivolumab + ipilimumab) already approved in various cancers, but the quadruple regimen itself is in early-phase investigation, particularly in solid tumors, including advanced/metastatic epithelial tumors.